Peptide Research Roundup — April 2026

What We're Watching This Month

Every month, we curate the most significant developments in peptide research from published literature and the broader scientific community. April 2026 brings several noteworthy findings across tissue repair, skin regeneration, and metabolic research.

This roundup is designed for researchers who want to stay current without spending hours on PubMed. We link each finding to the relevant Peptify product for convenience.

BPC-157: New Tendon Healing Data

Recent preclinical studies continue to strengthen the evidence base for BPC-157 in connective tissue repair. Published findings in early 2026 demonstrate accelerated Achilles tendon healing in rodent models, with researchers noting significant improvements in collagen organisation and tensile strength at the injury site.

BPC-157’s mechanism appears to involve upregulation of growth hormone receptor expression and enhanced VEGF-mediated angiogenesis at the injury site. The consistency of results across multiple research groups adds weight to these findings.

Relevant products: BPC-157 5mg (£14.99) and BPC-157 10mg (£26.99) from Peptify UK.

GHK-Cu: Collagen Synthesis in Skin Research

Copper peptide GHK-Cu continues to attract attention in dermatological research. Studies published in Q1 2026 have further quantified its effect on collagen types I and III synthesis in human dermal fibroblast cultures, with researchers reporting dose-dependent increases in procollagen expression.

Particularly interesting is the emerging research on GHK-Cu’s antioxidant gene regulation, where it appears to modulate over 30 genes involved in oxidative stress response. This positions it as one of the most multifunctional peptides in the skin research space.

Peptify offers GHK-Cu in 50mg (£18.99) and 100mg (£27.99) vials, plus the GLOW Blend 70mg (£69.99) which combines GHK-Cu with BPC-157 and TB-500.

Retatrutide: The Triple-Agonist Gaining Momentum

Retatrutide (LY-3437943) has dominated metabolic peptide discussions in 2026. As the first triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, it represents a new class of multi-pathway metabolic compounds.

Phase 2 clinical data published late 2025 showed unprecedented efficacy metrics compared to dual-agonist compounds. Researchers are now investigating the glucagon receptor component’s contribution to hepatic fat oxidation and energy expenditure.

Peptify stocks Retatrutide in 5mg (£49.99) and 10mg (£64.99) vials, both at 99%+ purity with full COA.

Selank + Semax: Nootropic Stacking Gains Interest

The combination of Selank (anxiolytic) and Semax (nootropic) continues to gain traction in cognitive neuroscience research. The complementary mechanisms — Selank modulating serotonin and GABA systems while Semax upregulates BDNF and NGF — provide a broader neurochemical coverage than either peptide alone.

Researchers are particularly interested in the dual BDNF pathway activation and its implications for neuroplasticity and stress resilience studies.

Peptify offers both peptides individually (Selank 10mg at £24.99, Semax 10mg at £34.99) and as a pre-blended Selank + Semax 20mg (£44.99).

Looking Ahead: May 2026

Next month we’ll be covering new data on MOTS-C exercise mimetic properties, TB-500 in cardiac tissue repair models, and the latest on NAD+ precursor research and mitochondrial longevity pathways.

Subscribe to our newsletter or follow us on social media to get the May roundup delivered to your inbox.